Antonio Cubillo

Spanish National Cancer Research Centre — Spain

Medicine · Health Sciences

24h-index3.0kcitations184works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(81), Cancer Genomics and Diagnostics(53), Pancreatic and Hepatic Oncology Research(40), Genetic factors in colorectal cancer(32), Cancer Treatment and Pharmacology(20)

Publications184 total

Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis
Nature Communications·2026Open Access
Inside GEMA 5.5: Expert Insights on the Latest Changes in Asthma Management
Archivos de Bronconeumología·2025
Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis
Nature Communications·2025· 1 citedOpen Access
A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX
American Journal of Clinical Oncology·2025
Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapy
Journal of Gastrointestinal Oncology·2025· 1 citedOpen Access
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain
Therapeutic Advances in Medical Oncology·2025· 4 citedOpen Access
Phase 2, Multicenter, Open-label, Nonrandomized Study of Neoadjuvant Chemotherapy Liposomal Irinotecan With 5-Fluorouracil, Leucovorin, and Oxaliplatin, Followed by Chemoradiotherapy in Patients With Rectal Cancer in a Watch-and-Wait Program
American Journal of Clinical Oncology·2024
157TiP A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD): The CORRECT-MRD I study
Annals of Oncology·2024Open Access
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
BMC Cancer·2024· 5 citedOpen Access
Light and shadow of watch-and-wait strategy in rectal cancer: oncological result, clinical outcomes, and cost-effectiveness analysis
International Journal of Colorectal Disease·2023· 12 cited
Light and shadow of Watch-and-wait strategy in rectal cancer. Oncological result, clinical outcomes after salvage surgery and cost effectiveness analysis. Experience of a single centre.
Research Square (Research Square)·2023Open Access
932P Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Annals of Oncology·2023· 2 citedOpen Access
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
BMC Cancer·2023· 10 citedOpen Access
P-182 Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer
Annals of Oncology·2023Open Access
Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.
Journal of Clinical Oncology·2023· 3 cited
Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.
Journal of Clinical Oncology·2023· 2 cited
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications·2023· 46 citedOpen Access
Table S1 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
2023Open Access
Legends supplementary Figures 1-6 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
2023Open Access
Figure S5 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Yolanda Quijano(10), Jesús Rodríguez-Pascual(10), Manuel Hidalgo(10), Emilio Vicente(7), Rafael Álvarez(6), Emiliano Calvo(6), Carlos Plaza(5), Fernando López‐Ríos(5), Carmen Rubio(5), Rocio García‐Carbonero(5), Ramón Salazar(4), Josep Tabernero(4), Sofía Perea(4), Carlos López(4), Valentina Boni(4), Andrea Wang‐Gillam(3), Teresa Macarulla(3), Richard Hubner(3), Jens T. Siveke(3), Bruce Belanger(3)